Skip to main content
SpringerLink
Log in

Gastric Cancer (Siewert Type III)

  • Chapter
  • First Online:
Gastrointestinal Malignancies

Part of the book series: Practical Guides in Radiation Oncology ((PGRO))

  • 1133 Accesses

Abstract

Gastric cancer is an aggressive gastrointestinal malignancy for which local and distant failures are common following surgical resection. Even among surgical series from experienced, high-volume centers, 5-year overall survival following extended surgical resections is generally less than 60%. As such, numerous studies have investigated the use of neoadjuvant or adjuvant therapies with chemotherapy, radiation, or concurrent chemoradiotherapy to improve long-term treatment outcomes. While the optimal adjuvant treatment regimen for resected gastric cancer is not clear, adjuvant chemotherapy and adjuvant chemoradiation have both demonstrated significant improvements in OS, even following maximal surgical resection. This chapter provides a guide for utilizing radiotherapy-containing regimens for the adjuvant treatment of gastric cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Park DJ, Lee HJ, Kim HH, Yang HK, Lee KU, Choe KJ. Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92(9):1099–102.

    Article  CAS  PubMed  Google Scholar 

  2. Smith DL, Elting LS, Learn PA, Raut CP, Mansfield PF. Factors influencing the volume-outcome relationship in gastrectomies: a population-based study. Ann Surg Oncol. 2007;14(6):1846–52.

    Article  PubMed  Google Scholar 

  3. Hamashima C, Shibuya D, Yamazaki H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38(4):259–67.

    Article  PubMed  Google Scholar 

  4. Lee KS, Oh DK, Han MA, et al. Gastric cancer screening in Korea: report on the national cancer screening program in 2008. Cancer Res Treat. 2011;43(2):83–8.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Schmidt B, Yoon SS. D1 versus D2 lymphadenectomy for gastric cancer. J Surg Oncol. 2013;107(3):259–64.

    Article  PubMed  Google Scholar 

  6. Verdecchia A, Mariotto A, Gatta G, Bustamante-Teixeira MT, Ajiki W. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer. 2003;39(11):1603–9.

    Article  CAS  PubMed  Google Scholar 

  7. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol. 1998;93(4):536–41.

    Article  CAS  PubMed  Google Scholar 

  8. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7(4):309–15.

    Article  CAS  PubMed  Google Scholar 

  9. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer. 1999;79(9–10):1522–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.

    Article  CAS  PubMed  Google Scholar 

  11. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  12. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.

    Article  CAS  PubMed  Google Scholar 

  13. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7.

    Article  CAS  PubMed  Google Scholar 

  14. Shapiro J, van Lanschot JJ, Hulshof MC, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.

    Article  PubMed  Google Scholar 

  15. Martin-Romano P, Sola JJ, Diaz-Gonzalez JA, et al. Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. Br J Cancer. 2016;115(6):655–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kim MS, Lim JS, Hyung WJ, et al. Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World J Gastroenterol. 2015;21(9):2711–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Trip AK, Poppema BJ, van Berge Henegouwen MI, et al. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiother Oncol. 2014;112(2):284–8.

    Article  PubMed  Google Scholar 

  18. Inoue T, Yachida S, Usuki H, et al. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. Ann Surg Oncol. 2012;19(9):2937–45.

    Article  PubMed  Google Scholar 

  19. Santoro R, Ettorre GM, Santoro E. Subtotal gastrectomy for gastric cancer. World J Gastroenterol. 2014;20(38):13667–80.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Gennari L, Bozzetti F, Bonfanti G, et al. Subtotal versus total gastrectomy for cancer of the lower two-thirds of the stomach: a new approach to an old problem. Br J Surg. 1986;73(7):534–8.

    Article  CAS  PubMed  Google Scholar 

  21. Santoro E, Garofalo A, Scutari F, Zanarini T, Carlini M, Santoro E Jr. Early gastric cancer: total gastrectomy vs. distal resection. Results of a study of 271 cases. The Italian Stomach Cancer Group (A.C.O.I.-I.S.C.G.). Hepato-Gastroenterology. 1991;38(5):427–9.

    CAS  PubMed  Google Scholar 

  22. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg. 1999;230(2):170–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg. 1987;11(4):418–25.

    Article  CAS  PubMed  Google Scholar 

  24. Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.

    Article  Google Scholar 

  25. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  26. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–16.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.

    Article  CAS  PubMed  Google Scholar 

  28. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996;347(9007):995–9.

    Article  CAS  PubMed  Google Scholar 

  30. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.

    Article  PubMed  Google Scholar 

  31. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreas-preserving total gastrectomy for proximal gastric cancer. World J Surg. 1995;19(4):532–6.

    Article  CAS  PubMed  Google Scholar 

  32. Uyama I, Ogiwara H, Takahara T, et al. Spleen- and pancreas-preserving total gastrectomy with superextended lymphadenectomy including dissection of the para-aortic lymph nodes for gastric cancer. J Surg Oncol. 1996;63(4):268–70.

    Article  CAS  PubMed  Google Scholar 

  33. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg. 2006;93(5):559–63.

    Article  CAS  PubMed  Google Scholar 

  34. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg. 2000;232(3):362–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Smith JW, Brennan MF, Botet JF, Gerdes H, Lightdale CJ. Pre endoscopic ultrasound can predict the risk of recurrence after operation for gastric carcinoma. J Clin Oncol. 1993;11(12):2380–5.

    Article  CAS  PubMed  Google Scholar 

  37. Bentrem D, Gerdes H, Tang L, Brennan M, Coit D. Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol. 2007;14(6):1853–9.

    Article  PubMed  Google Scholar 

  38. Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191(1):134–8.

    Article  PubMed  Google Scholar 

  39. Huang CM, Lin JX, Zheng CH, et al. Prognostic impact of dissected lymph node count on patients with node-negative gastric cancer. World J Gastroenterol. 2009;15(31):3926–30.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Vashakmadze LA, Babaian LA, Talaev MI, Koliadiuk IV, Savinov VA. Results of the combined treatment of cancer of the cardial region of the stomach (a cooperative, randomized study). Vopr Onkol. 1987;33(3):70–4.

    CAS  PubMed  Google Scholar 

  41. Talaev MI, Starinskii VV, Kovalev BN, et al. Results of combined treatment of cancer of the gastric antrum and gastric body. Vopr Onkol. 1990;36(12):1485–8.

    CAS  PubMed  Google Scholar 

  42. Shchepotin IB, Evans SR, Chorny V, et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg Oncol. 1994;3(1):37–44.

    Article  CAS  PubMed  Google Scholar 

  43. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC)--report on 370 patients. Int J Radiat Oncol Biol Phys. 1998;42(5):929–34.

    Article  CAS  PubMed  Google Scholar 

  44. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Michel P, Breysacher G, Mornex F, et al. Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Federation Francophone de Cancerologie Digestive 0308. Eur J Cancer. 2014;50(6):1076–83.

    Article  PubMed  Google Scholar 

  46. Rostom Y, Zaghloul H, Khedr G, El-Shazly W, Abd-Allah D. Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome. J Gastrointest Cancer. 2013;44(2):162–9.

    Article  CAS  PubMed  Google Scholar 

  47. Pera M, Gallego R, Montagut C, et al. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012;23(3):664–70.

    Article  CAS  PubMed  Google Scholar 

  48. Lee MS, Mamon HJ, Hong TS, et al. Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer. Oncologist. 2013;18(3):281–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Abe M, Yabumoto E, Takahashi M, Tobe T, Mori K. Intraoperative radiotherapy of gastric cancer. Cancer. 1974;34(6):2034–41.

    Article  CAS  PubMed  Google Scholar 

  50. Ogata T, Araki K, Matsuura K, et al. A 10-year experience of intraoperative radiotherapy for gastric carcinoma and a new surgical method of creating a wider irradiation field for cases of total gastrectomy patients. Int J Radiat Oncol Biol Phys. 1995;32(2):341–7.

    Article  CAS  PubMed  Google Scholar 

  51. Drognitz O, Henne K, Weissenberger C, et al. Long-term results after intraoperative radiation therapy for gastric cancer. Int J Radiat Oncol Biol Phys. 2008;70(3):715–21.

    Article  PubMed  Google Scholar 

  52. Abe M, Takahashi M, Ono K, Tobe T, Inamoto T. Japan gastric trials in intraoperative radiation therapy. Int J Radiat Oncol Biol Phys. 1988;15(6):1431–3.

    Article  CAS  PubMed  Google Scholar 

  53. Noyes RD, Weiss SM, Krall JM, et al. Surgical complications of intraoperative radiation therapy: the Radiation Therapy Oncology Group experience. J Surg Oncol. 1992;50(4):209–15.

    Article  CAS  PubMed  Google Scholar 

  54. Qin HL, Lin CH, Zhang XL. Evaluation of intraoperative radiotherapy for gastric carcinoma with D2 and D3 surgical resection. World J Gastroenterol. 2006;12(43):7033–7.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol. 2000;26(8):773–9.

    Article  CAS  PubMed  Google Scholar 

  56. Avizonis VN, Buzydlowski J, Lanciano R, Owens JC, Noyes RD, Hanks GE. Treatment of adenocarcinoma of the stomach with resection, intraoperative radiotherapy, and adjuvant external beam radiation: a phase II study from Radiation Therapy Oncology Group 85-04. Ann Surg Oncol. 1995;2(4):295–302.

    Article  CAS  PubMed  Google Scholar 

  57. Calvo FA, Aristu JJ, Azinovic I, et al. Intraoperative and external radiotherapy in resected gastric cancer: updated report of a phase II trial. Int J Radiat Oncol Biol Phys. 1992;24(4):729–36.

    Article  CAS  PubMed  Google Scholar 

  58. Furuse J, Ogino T, Ryu M, et al. Intraoperative and conformal external-beam radiation therapy in patients with locally advanced pancreatic carcinoma; results from a feasibility phase II study. Hepato-Gastroenterology. 2000;47(34):1142–6.

    CAS  PubMed  Google Scholar 

  59. Zhang Q, Tey J, Peng L, et al. Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma. Radiother Oncol. 2012;102(1):51–5.

    Article  PubMed  Google Scholar 

  60. Chen SS, Yang XC, Chi F, et al. A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma. Oncol Res. 2013;20(7):327–32.

    Article  CAS  PubMed  Google Scholar 

  61. Chen W, Shen J, Pan T, et al. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Exp Ther Med. 2014;7(2):461–7.

    Article  CAS  PubMed  Google Scholar 

  62. Wang Y, Yu YY, Li W, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014;73(6):1155–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Jary M, Ghiringhelli F, Jacquin M, et al. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemother Pharmacol. 2014;74(1):141–50.

    Article  CAS  PubMed  Google Scholar 

  64. Hirakawa M, Sato Y, Ohnuma H, et al. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemother Pharmacol. 2013;71(3):789–97.

    Article  CAS  PubMed  Google Scholar 

  65. Oki E, Emi Y, Kusumoto T, et al. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer. Ann Surg Oncol. 2014;21(7):2340–6.

    Article  PubMed  Google Scholar 

  66. Kosaka T, Akiyama H, Makino H, et al. Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemother Pharmacol. 2014;73(2):281–5.

    Article  CAS  PubMed  Google Scholar 

  67. Fazio N, Biffi R, Maibach R, et al. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. Ann Oncol. 2016;27(4):668–73.

    Article  CAS  PubMed  Google Scholar 

  68. Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30(6):643–9.

    Article  CAS  PubMed  Google Scholar 

  69. Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28(35):5210–8.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Basi A, Sohrabkhani S, Zamani F, et al. Comparing efficacy of preoperative neo-adjuvant chemotherapy and surgery versus surgery alone in patients with resectable gastroesophageal cancer. Int J Hematol Oncol Stem Cell Res. 2013;7(4):24–8.

    PubMed  PubMed Central  Google Scholar 

  71. Ferri LE, Ades S, Alcindor T, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012;23(6):1512–7.

    Article  CAS  PubMed  Google Scholar 

  72. Alcindor T, Ferri LE, Marcus V, et al. Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome. Med Oncol. 2013;30(1):377.

    Article  CAS  PubMed  Google Scholar 

  73. Thuss-Patience PC, Hofheinz RD, Arnold D, et al. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. Ann Oncol. 2012;23(11):2827–34.

    Article  CAS  PubMed  Google Scholar 

  74. Peng YF, Imano M, Itoh T, et al. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. J Surg Oncol. 2015;111(8):1041–6.

    Article  CAS  PubMed  Google Scholar 

  75. Kim YW, Kim MJ, Ryu KW, et al. A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2016;19(2):586–96.

    Article  CAS  PubMed  Google Scholar 

  76. Schulz C, Kullmann F, Kunzmann V, et al. NeoFLOT: multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015;137(3):678–85.

    Article  CAS  PubMed  Google Scholar 

  77. Tanz R, El Mhadi C, Toreis M, et al. FOLFOX as Perioperative Chemotherapy of localized Gastric Cancer: Efficacy and Tolerance. Gulf J Oncolog. 2016;1(21):17–20.

    CAS  PubMed  Google Scholar 

  78. Mary F, Zaanan A, Boige V, et al. Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. Dig Liver Dis. 2016;48(12):1498–502.

    Article  CAS  PubMed  Google Scholar 

  79. Shim HJ, Kim KR, Hwang JE, et al. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. Cancer Chemother Pharmacol. 2016;77(3):605–12.

    Article  CAS  PubMed  Google Scholar 

  80. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet. 1994;343(8909):1309–12.

    Article  CAS  PubMed  Google Scholar 

  81. Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11(8):1441–7.

    Article  CAS  PubMed  Google Scholar 

  82. Nakajima T, Nashimoto A, Kitamura M, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet. 1999;354(9175):273–7.

    Article  CAS  PubMed  Google Scholar 

  83. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.

    Article  CAS  PubMed  Google Scholar 

  84. Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315–21.

    Article  CAS  PubMed  Google Scholar 

  85. Kim S, Lim DH, Lee J, et al. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach. Int J Radiat Oncol Biol Phys. 2005;63(5):1279–85.

    Article  PubMed  Google Scholar 

  86. Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with Capecitabine and Cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.

    Article  CAS  PubMed  Google Scholar 

  87. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.

    Article  CAS  PubMed  Google Scholar 

  88. Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84(5):e585–92.

    Article  CAS  PubMed  Google Scholar 

  89. Leong T, Joon DL, Willis D, et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2011;79(3):690–5.

    Article  CAS  PubMed  Google Scholar 

  90. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16(5):1826–34.

    Article  CAS  PubMed  Google Scholar 

  91. Lee HS, Choi Y, Hur WJ, et al. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol. 2006;12(4):603–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Schwartz GK, Winter K, Minsky BD, et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114). J Clin Oncol. 2009;27(12):1956–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Feng M, Balter JM, Normolle D, et al. Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys. 2009;74(3):884–91.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Lever FM, Lips IM, Crijns SP, et al. Quantification of esophageal tumor motion on cine-magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2014;88(2):419–24.

    Article  PubMed  Google Scholar 

  95. Heinzerling JH, Bland R, Mansour JC, et al. Dosimetric and motion analysis of margin-intensive therapy by stereotactic ablative radiotherapy for resectable pancreatic cancer. Radiat Oncol. 2011;6:146.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Reese AS, Lu W, Regine WF. Utilization of intensity-modulated radiation therapy and image-guided radiation therapy in pancreatic cancer: is it beneficial? Semin Radiat Oncol. 2014;24(2):132–9.

    Article  PubMed  Google Scholar 

  97. Aggarwal A, Chopra S, Paul SN, Engineer R, Srivastava SK. Evaluation of internal target volume in patients undergoing image-guided intensity modulated adjuvant radiation for gastric cancers. Br J Radiol. 2014;87(1033):20130583.

    Article  CAS  PubMed  Google Scholar 

  98. Wunderink W, Mendez Romero A, de Kruijf W, de Boer H, Levendag P, Heijmen B. Reduction of respiratory liver tumor motion by abdominal compression in stereotactic body frame, analyzed by tracking fiducial markers implanted in liver. Int J Radiat Oncol Biol Phys. 2008;71(3):907–15.

    Article  PubMed  Google Scholar 

  99. Campbell W, Miften M, Schefter T, Goodman K, Jones B. TH-CD-207A-04: optimized respiratory gating for abnormal breathers in pancreatic SBRT. Med Phys. 2016;43(6):3880.

    Article  Google Scholar 

  100. Wong JW, Sharpe MB, Jaffray DA, et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys. 1999;44(4):911–9.

    Article  CAS  PubMed  Google Scholar 

  101. Latty D, Stuart KE, Wang W, Ahern V. Review of deep inspiration breath-hold techniques for the treatment of breast cancer. J Med Radiat Sci. 2015;62(1):74–81.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Kubo HD, Len PM, Minohara S, Mostafavi H. Breathing-synchronized radiotherapy program at the University of California Davis Cancer Center. Med Phys. 2000;27(2):346–53.

    Article  CAS  PubMed  Google Scholar 

  103. Giraud P, Garcia R. Respiratory gating for radiotherapy: main technical aspects and clinical benefits. Bull Cancer. 2010;97(7):847–56.

    CAS  PubMed  Google Scholar 

  104. Tada T, Minakuchi K, Fujioka T, et al. Lung cancer: intermittent irradiation synchronized with respiratory motion--results of a pilot study. Radiology. 1998;207(3):779–83.

    Article  CAS  PubMed  Google Scholar 

  105. Shiinoki T, Hanazawa H, Yuasa Y, Fujimoto K, Uehara T, Shibuya K. Verification of respiratory-gated radiotherapy with new real-time tumour-tracking radiotherapy system using cine EPID images and a log file. Phys Med Biol. 2017;62(4):1585–99.

    Article  PubMed  Google Scholar 

  106. Fung A, Li C, Torres C. TH-AB-202-07: radar tracking of respiratory motion in real time. Med Phys. 2016;43(6):3858.

    Article  Google Scholar 

  107. Han F, Zhou Z, Yang Y, Sheng K, Hu P. SU-F-J-158: respiratory motion resolved, self-gated 4D-MRI using rotating Cartesian K-Space sampling. Med Phys. 2016;43(6):3444.

    Article  Google Scholar 

  108. Namysl-Kaletka A, Wydmanski J, Tukiendorf A, et al. Influence of interfraction motion on margins for radiotherapy of gastric cancer. Br J Radiol. 2015;88(1048):20140610.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Nam H, Lim DH, Kim S, et al. A new suggestion for the radiation target volume after a subtotal gastrectomy in patients with stomach cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):448–55.

    Article  PubMed  Google Scholar 

  110. Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S10–9.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiotherapy for isolated para-aortic lymph node recurrence after curative resection in gastric cancer. J Korean Med Sci. 2009;24(3):488–92.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Verma V, Lin SH, Simone CB 2nd, Mehta MP. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastrointest Oncol. 2016;7(4):644–64.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Dionisi F, Avery S, Lukens JN, et al. Proton therapy in adjuvant treatment of gastric cancer: planning comparison with advanced x-ray therapy and feasibility report. Acta Oncol. 2014;53(10):1312–20.

    Article  CAS  PubMed  Google Scholar 

  114. Chopra S, Agarwal A, Engineer R, et al. Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: a matched pair analysis. J Cancer Res Ther. 2015;11(3):623–9.

    Article  CAS  PubMed  Google Scholar 

  115. Hu X, He W, Wen S, et al. Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A meta-analysis. PLoS One. 2016;11(4):e0151988.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  116. Bittner MI, Grosu AL, Brunner TB. Comparison of toxicity after IMRT and 3D-conformal radiotherapy for patients with pancreatic cancer—a systematic review. Radiother Oncol. 2015;114(1):117–21.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of lowa, lowa City, IA, USA

    Joseph M. Caster M.D., Ph.D.

  2. University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Joel E. Tepper M.D.

Authors
  1. Joseph M. Caster M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel E. Tepper M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio, USA

    Suzanne Russo

  2. Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida, USA

    Sarah Hoffe

  3. Department of Radiation Oncology, University of Washington School of Medicine, Seattle, Washington, USA

    Edward Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Caster, J.M., Tepper, J.E. (2018). Gastric Cancer (Siewert Type III). In: Russo, S., Hoffe, S., Kim, E. (eds) Gastrointestinal Malignancies. Practical Guides in Radiation Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-64900-9_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64900-9_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64899-6

  • Online ISBN: 978-3-319-64900-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation